Fujifilm, Kyowa Hakko Kirin deal

The partners launched the Fujifilm Kyowa Kirin Biologics Co. Ltd. (Tokyo, Japan) 50/50 JV which will develop biosimilars. Both partners contributed ¥50 million ($0.6 million) to the JV, which plans to start clinical trials early next year for a biosimilar of adalimumab. The JV expects to get its biosimilar adalimumab to market four to five years after the start of clinical trials. Additionally, the JV plans to move one biosimilar into the clinic every year after 2014. Kyowa and Fujifilm announced plans to form the JV last year (see BioCentury, Nov. 21, 2011). ...